Welcome to our dedicated page for Kalaris Therapeutics news (Ticker: KLRS), a resource for investors and traders seeking the latest updates and insights on Kalaris Therapeutics stock.
Kalaris Therapeutics develops clinical-stage biopharmaceutical treatments for retinal diseases, with company updates centered on TH103, its investigational biologic for neovascular age-related macular degeneration and other sight-threatening retinal conditions.
Recurring news includes Phase 1 clinical data, safety and pharmacokinetic presentations, manufacturing and clinical-supply arrangements, financial results and cash runway commentary, capital actions, healthcare conference presentations, and leadership changes as the company advances its retinal-disease program.
Kalaris (Nasdaq: KLRS) reported first quarter 2026 results and clinical progress for retinal drug TH103. Patient screening is underway in the Phase 1b/2 nAMD study, with preliminary data expected in 1H 2027 and Phase 3 trials targeted to start by year-end 2027.
Kalaris reported $104.9 million in cash, cash equivalents and marketable securities as of March 31, 2026, expected to fund operations into Q4 2027. Q1 2026 R&D expenses were $7.6 million, G&A expenses were $4.3 million, and net loss was $10.9 million.
Kalaris (Nasdaq: KLRS) reported full year 2025 results and business updates on March 17, 2026. Key developments include positive Phase 1a nAMD data showing mean 10‑letter BCVA improvement, mean 129μm CST reduction, ~95% intraretinal fluid reduction and 27–51x lower plasma Cmax versus leading anti‑VEGF agents.
Financials: completed a $50.0M private placement, held $118.0M in cash and marketable securities at 12/31/2025, and expects that funding into Q4 2027; 2025 net loss was $43.4M.
Kalaris (NASDAQ: KLRS) will present Phase 1 clinical data for TH103 at the Macula Society Annual Meeting, Feb 25-28, 2026 in San Diego.
The Feb 26 presentation by Dean Eliott, MD will cover safety, tolerability, pharmacokinetics and early efficacy after intravitreal dosing in treatment‑naive neovascular AMD.
Kalaris Therapeutics (NASDAQ: KLRS) entered a securities purchase agreement for an oversubscribed private placement to raise approximately $50.0 million gross, expected to close on or about December 19, 2025.
The financing consists of 4,200,000 common shares at $10.00 per share and 800,000 pre-funded warrants at $9.9999 each (exercise price $0.0001), with resale registration rights to be filed with the SEC. Morgan Stanley, Leerink Partners, and William Blair act as placement agents.
Based on current plans, management expects the net proceeds plus existing cash will fund operations into the third quarter of 2027, and proceeds will advance clinical development of TH103 for neovascular AMD and for general corporate purposes.
Kalaris Therapeutics (NASDAQ: KLRS) reported positive initial Phase 1a single ascending dose data for TH103 in treatment‑naïve neovascular AMD (N=13) with three dose levels (0.5 mg, 1.5 mg, 2.5 mg) and 6 months follow‑up. Key outcomes at Month 1 included a mean +10‑letter BCVA, −129 μm central subfield thickness (CST), and ~95% reduction in central intraretinal fluid. Pharmacokinetics showed dose‑adjusted plasma Cmax 27–51‑fold lower versus current leading agents. After one injection, 31% of patients required no additional anti‑VEGF treatment through 6 months. Two transient cases of intraocular inflammation at 2.5 mg were attributed to host cell protein; manufacturing was updated and no new IOI cases were seen with purified material. Kalaris is accelerating its Phase 1b/2 multi‑ascending dose study and expects preliminary data in 2H 2026. Conference call/webcast held today at 4:30 PM ET.
Kalaris Therapeutics (Nasdaq: KLRS) announced that management will present at the Noble Capital Markets 21st Annual Emerging Growth Equity Conference.
Presentation details: Matthew Feinsod, Chief Medical Officer, will present on Wednesday, December 3, 2025 from 11:30–11:55 AM ET at Florida Atlantic University in Boca Raton, FL. Management will be available for one-on-one meetings by arrangement with conference representatives.
Kalaris (Nasdaq: KLRS) reported Q3 2025 results and business updates on Nov 12, 2025. The company had $77.0M in cash, cash equivalents and short-term investments as of Sep 30, 2025, which it expects will fund operations into 2027. Clinical progress includes a Phase 1a single ascending dose trial with initial data expected by year-end 2025 and a newly initiated Phase 1b/2 multiple ascending dose trial enrolling up to 80 nAMD patients with initial data expected in 2H 2026. Kalaris entered a formal CDMO agreement with KBI Biopharma, hired a new CFO, and opened headquarters in Berkeley Heights, NJ. Q3 net loss was $11.9M; shares outstanding were 18,702,418.
Kalaris (NASDAQ:KLRS) appointed Matthew Gall, MBA as Chief Financial Officer effective Nov 3, 2025.
The hire strengthens Kalaris’ leadership as the company enrolls its Phase 1b/2 study in treatment‑naïve nAMD patients. Gall previously served as CFO of iTeos Therapeutics and held finance and business development roles at Sarepta, Celgene, and Gilead. He holds a BS in Business Administration from Bowling Green State University and an MBA from The University of Chicago.
The company described the appointment as supporting capital strategy, business development and scaling during clinical advancement.
Kalaris (Nasdaq: KLRS) announced that company management will present at the Stifel 2025 Annual Healthcare Conference on Thursday, November 13, 2025 from 3:20–3:50pm ET at the Lotte New York Palace Hotel in New York, NY.
Speakers listed are Andrew Oxtoby, CEO, and Matthew Feinsod, CMO. Management will be available for one-on-one meetings during the conference; interested parties should contact their conference representative to arrange a meeting.
Kalaris Therapeutics (NASDAQ:KLRS) has begun enrolling patients in a Phase 1b/2 multiple ascending dose (MAD) study for TH103, targeting neovascular age-related macular degeneration (nAMD). The study will evaluate multiple dose levels in up to 80 nAMD patients, who will receive 4 monthly intravitreal injections.
The Phase 1b/2 study replaces a smaller Part 2 design and will inform dose selection for potential Phase 3 development. Initial data is expected in 2H 2026. Meanwhile, the ongoing Phase 1a single ascending dose study remains on schedule to report data in Q4 2025.
TH103, developed by Lasker Award recipient Dr. Napoleone Ferrara, represents a novel approach to treating exudative and neovascular retinal diseases, building on anti-VEGF therapy research.